Edwards Solidifies TAVR Dominance in Long-Term Trial Readout
Edwards Lifesciences' transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial readout, amidst increasing global demand for the technology.
The trial readouts showed TAVR's comparable performance to surgical aortic valve replacement treatment. The company presented seven-year data from its PARTNER 3 trial, reaffirming the benefits of its SAPIEN 3 TAVR system in low-risk patients with aortic stenosis compared to surgery.
The data was presented at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) meeting in San Francisco.
The gold standard of business intelligence.
Author's summary: Edwards Lifesciences' TAVR system shows positive results in long-term trial.
More News
- The Most Dazzling Looks From The Angel Ball's 2025 Red Carpet
- US Embassy in Mali urges Americans to leave ‘immediately’
- From WNBA Court To Playmate Glam: Check Out Kysre Gondrezick’s Sexiest Photos
- Al Nassr Al-Ittihad Jeddah 28 10 2025 Live Score and Match Summary
- Nick Offerman and Lee K. Buchanan Close Out Arts and Humanities Day with a Love Letter to Carpentry, Family, and the Pursuit of Hands-On Work in the Digital Age
- Al-Nassr 1-2 Al-Ittihad: Report, result and goals as Karim Benzema scores to knock Cristiano Ronaldo's side out of Kings Cup
- Travel-Ready Base Layers That Simplify Packing
- Sudan: North Darfur capital falls to RSF as UN warns of 'atrocities and mass displacement'
- Eintracht Frankfurt Borussia Dortmund 28 10 2025 Live Score and Match Summary
- Trump administration quietly purges ICE leaders in five cities, including Denver: Sources